Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 196

1.

Latent tuberculosis infection treatment for prison inmates: a randomised controlled trial.

Chan PC, Yang CH, Chang LY, Wang KF, Lu BY, Lu CY, Shao PL, Hsueh PR, Fang CT, Huang LM.

Int J Tuberc Lung Dis. 2012 May;16(5):633-8. doi: 10.5588/ijtld.11.0504.

PMID:
22410137
2.

Factors associated with treatment adherence in a randomised trial of latent tuberculosis infection treatment.

Trajman A, Long R, Zylberberg D, Dion MJ, Al-Otaibi B, Menzies D.

Int J Tuberc Lung Dis. 2010 May;14(5):551-9.

PMID:
20392347
3.

Changes in QuantiFERON®-TB Gold In-Tube results during treatment for tuberculous infection.

Bastos ML, Menzies D, Belo MT, Teixeira EG, de Abreu ST, Antas PR, Trajman A.

Int J Tuberc Lung Dis. 2013 Jul;17(7):909-16. doi: 10.5588/ijtld.12.0927.

PMID:
23743310
4.

Improved adherence and less toxicity with rifampin vs isoniazid for treatment of latent tuberculosis: a retrospective study.

Page KR, Sifakis F, Montes de Oca R, Cronin WA, Doherty MC, Federline L, Bur S, Walsh T, Karney W, Milman J, Baruch N, Adelakun A, Dorman SE.

Arch Intern Med. 2006 Sep 25;166(17):1863-70.

PMID:
17000943
5.

Rifampicin plus isoniazid for the prevention of tuberculosis in an immigrant population.

Jiménez-Fuentes MA, de Souza-Galvao ML, Mila Augé C, Solsona Peiró J, Altet-Gómez MN.

Int J Tuberc Lung Dis. 2013 Mar;17(3):326-32. doi: 10.5588/ijtld.12.0510.

PMID:
23407221
6.

Isoniazid vs. rifampin for latent tuberculosis infection in jail inmates: toxicity and adherence.

White MC, Tulsky JP, Lee JR, Chen L, Goldenson J, Spetz J, Kawamura LM.

J Correct Health Care. 2012 Apr;18(2):131-42. doi: 10.1177/1078345811435973.

7.

Effectiveness of 3 months of rifampicin and isoniazid chemoprophylaxis for the treatment of latent tuberculosis infection in children.

Bright-Thomas R, Nandwani S, Smith J, Morris JA, Ormerod LP.

Arch Dis Child. 2010 Aug;95(8):600-2. doi: 10.1136/adc.2010.182600.

PMID:
20530147
8.

Adherence to treatment of latent tuberculosis infection in a clinical population in New York City.

Li J, Munsiff SS, Tarantino T, Dorsinville M.

Int J Infect Dis. 2010 Apr;14(4):e292-7. doi: 10.1016/j.ijid.2009.05.007.

10.

Enhancement of treatment completion for latent tuberculosis infection with 4 months of rifampin.

Lardizabal A, Passannante M, Kojakali F, Hayden C, Reichman LB.

Chest. 2006 Dec;130(6):1712-7.

PMID:
17166986
11.

Potential cost-effectiveness of rifampin vs. isoniazid for latent tuberculosis: implications for future clinical trials.

Esfahani K, Aspler A, Menzies D, Schwartzman K.

Int J Tuberc Lung Dis. 2011 Oct;15(10):1340-6. doi: 10.5588/ijtld.10.0575.

PMID:
22283892
12.

[Short-course isoniazid and rifampin compared with isoniazid for latent tuberculosis infection: a randomized clinical trial].

Geijo MP, Herranz CR, Vaño D, García AJ, García M, Dimas JF.

Enferm Infecc Microbiol Clin. 2007 May;25(5):300-4. Spanish.

PMID:
17504682
13.

Management of latent Mycobacterium tuberculosis infection: WHO guidelines for low tuberculosis burden countries.

Getahun H, Matteelli A, Abubakar I, Aziz MA, Baddeley A, Barreira D, Den Boon S, Borroto Gutierrez SM, Bruchfeld J, Burhan E, Cavalcante S, Cedillos R, Chaisson R, Chee CB, Chesire L, Corbett E, Dara M, Denholm J, de Vries G, Falzon D, Ford N, Gale-Rowe M, Gilpin C, Girardi E, Go UY, Govindasamy D, D Grant A, Grzemska M, Harris R, Horsburgh CR Jr, Ismayilov A, Jaramillo E, Kik S, Kranzer K, Lienhardt C, LoBue P, Lönnroth K, Marks G, Menzies D, Migliori GB, Mosca D, Mukadi YD, Mwinga A, Nelson L, Nishikiori N, Oordt-Speets A, Rangaka MX, Reis A, Rotz L, Sandgren A, Sañé Schepisi M, Schünemann HJ, Sharma SK, Sotgiu G, Stagg HR, Sterling TR, Tayeb T, Uplekar M, van der Werf MJ, Vandevelde W, van Kessel F, van't Hoog A, Varma JK, Vezhnina N, Voniatis C, Vonk Noordegraaf-Schouten M, Weil D, Weyer K, Wilkinson RJ, Yoshiyama T, Zellweger JP, Raviglione M.

Eur Respir J. 2015 Dec;46(6):1563-76. doi: 10.1183/13993003.01245-2015. Review.

14.

Serial interferon-gamma release assays after rifampicin prophylaxis in a tuberculosis outbreak.

Lee SH, Lew WJ, Kim HJ, Lee HK, Lee YM, Cho CH, Lee EJ, Lee DY, Ryu SW, Oh SY, Kim SO, Shim TS.

Respir Med. 2010 Mar;104(3):448-53. doi: 10.1016/j.rmed.2009.10.006.

15.

Detection and management of latent tuberculosis in liver transplant patients.

Jafri SM, Singal AG, Kaul D, Fontana RJ.

Liver Transpl. 2011 Mar;17(3):306-14. doi: 10.1002/lt.22203.

16.
17.

Treatment for preventing tuberculosis in children and adolescents: a randomized clinical trial of a 3-month, 12-dose regimen of a combination of rifapentine and isoniazid.

Villarino ME, Scott NA, Weis SE, Weiner M, Conde MB, Jones B, Nachman S, Oliveira R, Moro RN, Shang N, Goldberg SV, Sterling TR; International Maternal Pediatric and Adolescents AIDS Clinical Trials Group.; Tuberculosis Trials Consortium..

JAMA Pediatr. 2015 Mar;169(3):247-55. doi: 10.1001/jamapediatrics.2014.3158. Erratum in: JAMA Pediatr. 2015 Sep;169(9):878.

PMID:
25580725
18.
19.

Adverse events and development of tuberculosis after 4 months of rifampicin prophylaxis in a tuberculosis outbreak.

Lee SH, Yim JJ, Kim HJ, Shim TS, Seo HS, Cho YS, Lee HK, Lee YM, Lee EJ, Lew WJ.

Epidemiol Infect. 2012 Jun;140(6):1028-35. doi: 10.1017/S0950268811001476.

PMID:
21835069
20.

Lower prevalence of tuberculosis infection in BCG vaccinees: a cross-sectional study in adult prison inmates.

Chan PC, Yang CH, Chang LY, Wang KF, Kuo YC, Lin CJ, Lee SW, Hsueh PR, Fang CT, Huang LM.

Thorax. 2013 Mar;68(3):263-8. doi: 10.1136/thoraxjnl-2012-202208.

PMID:
23019256
Items per page

Supplemental Content

Support Center